Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors

	Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
	2020
卷号	38 期号:15
	Wang Zhenguang; Chen Meixia; Zhang Yan; Liu Yang; Yang Qingming; Nie Jing; Shen Lianjun; Jiang Pengfei; He Jiaping; Ye Xun; Cao Wei; Wang HY(王皓毅); Han Weidong
文献类型	期刊论文
条目标识符	http://ir.ioz.ac.cn/handle/000000/14558
专题	干细胞与生殖生物学国家重点实验室
推荐引用方式 GB/T 7714	Wang Zhenguang,Chen Meixia,Zhang Yan,et al. Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY,2020,38(15).
APA	Wang Zhenguang.,Chen Meixia.,Zhang Yan.,Liu Yang.,Yang Qingming.,...&Han Weidong.(2020).Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors.JOURNAL OF CLINICAL ONCOLOGY,38(15).
MLA	Wang Zhenguang,et al."Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors".JOURNAL OF CLINICAL ONCOLOGY 38.15(2020).